首页> 外文期刊>Journal of Clinical Oncology >Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party.
【24h】

Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party.

机译:晚期非小细胞肺癌生存率的预后因素:单因素和多因素分析,包括1,052位患者的递归分配和合并算法。欧洲肺癌工作组。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: This study attempted to determine the prognostic value for survival of various pretreatment characteristics in patients with nonresectable non-small-cell lung cancer in the context of more than 10 years of experience of a European Cooperative Group. PATIENTS AND METHODS: We included in the analysis all eligible patients (N = 1,052) with advanced non-small-cell lung cancer registered onto one of seven trials conducted by the European Lung Cancer Working Party (ELCWP) during one decade. The patients were treated by chemotherapy regimens based on platinum derivatives. We prospectively collected 23 variables and analyzed them by univariate and multivariate methods. RESULTS: The global estimated median survival time was 29 weeks, with a 95% confidence interval of 27 to 30 weeks. After univariate analysis, we applied two multivariate statistical techniques. In a Cox regression model, the selected explanatory variables were disease extent, Karnofsky performance status, WBC and neutrophil counts, metastatic involvement of skin, serum calcium level, age, and sex. These results were confirmed by application of recursive partitioning and amalgamation algorithms (RECPAM), which led to classification of the patients into four homogeneous subgroups. CONCLUSION: We confirmed by our analysis the role of well-known independent prognostic factors for survival, but also identified the effect of the neutrophil count, rarely studied, with the use of two methods: a classical Cox regression model and a RECPAM analysis. The classification of patients into the four subgroups we obtained needs to be validated in other series.
机译:目的:本研究试图根据欧洲合作组织10多年的经验,确定不可切除的非小细胞肺癌患者各种预处理特征的生存的预后价值。病人和方法:我们纳入了所有分析合格的晚期非小细胞肺癌患者(N = 1,052),这些患者已登记进入由欧洲肺癌工作组(ELCWP)在十年中进行的七项试验之一。患者接受了基于铂衍生物的化疗方案的治疗。我们前瞻性地收集了23个变量,并通过单变量和多变量方法对其进行了分析。结果:全球估计的中位生存时间为29周,95%置信区间为27至30周。经过单变量分析后,我们应用了两种多元统计技术。在Cox回归模型中,选择的解释变量是疾病范围,Karnofsky行为状态,WBC和中性粒细胞计数,皮肤转移,血清钙水平,年龄和性别。这些结果通过应用递归分区和合并算法(RECPAM)得以证实,该算法将患者分为四个同质亚组。结论:我们通过分析证实了众所周知的独立预后因素对生存的作用,但还通过两种方法使用了经典的Cox回归模型和RECPAM分析,从而确定了很少研究的嗜中性白细胞计数的影响。我们将患者分为四个亚组的分类需要在其他系列中进行验证。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号